Link Asia International MedTech : VOLUNTARY ANNOUNCEMENT IN RELATION TO ENTERING INTO THE STRATEGIC INVESTMENT MEMORANDUM

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Link-Asia International MedTech Group Limited

環 亞 國 際 醫 療 科 技 集 團 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

VOLUNTARY ANNOUNCEMENT

IN RELATION TO

ENTERING INTO THE STRATEGIC INVESTMENT MEMORANDUM

This announcement is made on a voluntary basis by Link-Asia International MedTech Group Limited (the ''Company'', together with its subsidiaries, the ''Group'') to provide the shareholders (the ''Shareholders'') and potential investors of the Company with updated information in relation to the latest business development of the Group.

THE STRATEGIC INVESTMENT MEMORANDUM

The board (the ''Board'') of directors of the Company is pleased to announce that, on 21 April 2021 (after trading hours), Link-Asia Medtech Investment Limited (環亞醫療科技投資 有限公司) (''Link-AsiaInvestment''), which is a wholly-owned subsidiary of the Company, entered into a strategic investment memorandum (the ''Memorandum'') with Nanjing Jilang Biotechnology Co., Ltd (南京濟朗生物科技有限公司) (the ''Nanjing Jilang'') and Mr. Zhu Shuhan (''Mr. Zhu'').

According to the Memorandum, Link-Asia Investment has intention to invest and hold approximately 15% equity shares of Nanjing Jilang. The Company shall conduct a due diligence review on Nanjing Jilang within 90 days upon signing of the Memorandum. Subject to the results of the aforesaid due diligence review being satisfied to the Company, Link-Asia Investment and Nanjing Jilang shall enter into a formal investment agreement.

INFORMATION ABOUT NANJING JILANG

Nanjing Jilang is a company established in China with limited liability, its principal business is the research in early-stage biological diagnosis technology related to female reproductive health.

According to the information provided by Nanjing Jilang and enquiry by the Company, as at the date of this announcement, Mr. Zhu, Nanjing Shilang Investment Management Center (Limited Partnership) (南京世朗投資管理中心(有限合夥)), Jiangsu Jiequan Xiantong Biomedical Venture Capital Partnership (Limited Partnership) (江蘇疌泉仙瞳生物醫療創業

- 1 -

投資合夥企業), Mr. Gu Yongchuan, Ms. Yin Zuowei, Ma Yinglong Pharmaceutical Group Co., Ltd., Hubei Gaolong Health Industry Investment Fund Partnership (Limited Partnership) (湖北高龍健康產業投資基金合夥企業), and Nanjing Baojun Venture Capital Fund (Limited Partnership) (南京寶駿創業投資基金(有限合夥)) hold 47.3%, 14.822%, 9.86%, 8%, 8%, 5.564%, 3.334% and 3.12% equity shares of Nanjing Jilang respectively. To the best of knowledge, information and belief of the directors of the Company having made all reasonable enquiries, as at the date of this announcement, the controlling shareholder of Nanjing Jilang (Mr. Zhu), its substantial shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the ''Listing Rules'')) and their ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Listing Rules).

REASONS FOR AND BENEFITS OF THE STRATEGIC INVESTMENT

The Group is principally engaged in (i) electronic manufacturing services; (ii) marketing and distribution of communication products; (iii) real estate supply chain services; and (iv) the securities and other assets investment.

As disclosed in the previous announcements, the Board and the management of the Company are not only dedicated to developing the Group's existing core businesses but are actively exploring new business, especially the assisted reproductive medical technology business with huge market demand, and has been carrying out the layout in this industry.

Nanjing Jilang has been focusing on the research and development of serialized non-invasive rapid monitoring for reproductive health and in vitro diagnostic products. Nanjing Jilang owns the patent of ''Fast Non-invasive Monitoring Technology for Female Luteal Function'' and its core product, the non-invasive rapid detection of female hormone (PdG) kit, is close to the completion of clinical trials. This non-invasive sex hormone monitoring technology fills the gap in the domestic non-invasive monitoring field of female reproductive health, and may implement dynamic monitoring of the whole process from pregnancy preparation, pre-pregnancy diagnosis to post-pregnancy monitoring, which will meet the huge needs of domestic female group of infertility, assisted reproduction, prenatal and postnatal care.

The Board believes that Nanjing Jilang's non-invasive sex hormone monitoring technology is innovative and could be widely used in ovulation prediction, hormone diagnosis testing for infertility, early fetal health monitoring and other fields, which could facilitate the dynamic detection and monitoring of hormone levels of infertile and eugenic women, and improve the success rate of pregnancy preparation and assistance. If the strategic investment can be materialized, it will broaden the layout of assisted reproductive medical technology industry chain of the Group, enrich the relevant technical reserves, and bring synergy to the Group in the development of the assisted reproductive service business.

GENERAL

The Board wishes to emphasize that as at the date of this announcement, the Company has not yet entered into a legally-binding agreement in relation to the proposed investment in Nanjing Jilang. The investment, if materialized, may constitute a notifiable transaction for the Company under the Listing Rules. Further announcement(s) will be made by the Company as and when appropriate in compliance with the Listing Rules.

- 2 -

Shareholders and potential investors of the Company should note that the possible investment may or may not proceed and are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board

Link-Asia International MedTech Group Limited

Lin Dailian

Chairman and executive director

Hong Kong, 21 April 2021

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Mr. Xia Xiaobing as executive directors; Mr. Li Huiwu and Mr. Yang Weidong as independent non-executive directors.

- 3 -